BIOMEA FUSION INC (BMEA) Stock Overview
USA - NASDAQ:BMEA - US09077A1060 - Common Stock
BMEA Key Statistics, Chart & Performance
The current stock price of BMEA is 1.33 USD. In the past month the price decreased by -37.56%. In the past year, price decreased by -85.29%.
BMEA Latest News, Press Relases and Analysis
BMEA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 14.46 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.82 | 58.93B | ||
| ARGX | ARGENX SE - ADR | 61.91 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.97 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 8.94 | 21.93B |
Related stock screener links
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 63 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Company Info
BIOMEA FUSION INC
1599 Industrial Road
San Carlos CALIFORNIA US
Employees: 63
Phone: 16509809099
BIOMEA FUSION INC / BMEA FAQ
What does BMEA do?
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 63 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
What is the current price of BMEA stock?
The current stock price of BMEA is 1.33 USD. The price decreased by -2.92% in the last trading session.
Does BIOMEA FUSION INC pay dividends?
BMEA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BMEA stock?
BMEA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BMEA stock to perform?
13 analysts have analysed BMEA and the average price target is 8.16 USD. This implies a price increase of 513.53% is expected in the next year compared to the current price of 1.33.
What is the ownership structure of BIOMEA FUSION INC (BMEA)?
You can find the ownership structure of BIOMEA FUSION INC (BMEA) on the Ownership tab.
BMEA Technical Analysis
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. BMEA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 22.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -153.21% | ||
| ROE | -407.46% | ||
| Debt/Equity | 0 |
BMEA Forecast & Estimates
13 analysts have analysed BMEA and the average price target is 8.16 USD. This implies a price increase of 513.53% is expected in the next year compared to the current price of 1.33.